In most clinical settings, ipsilateral UAL after recent COVID-19 vaccination is benign finding; clinical follow-up recommended<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, March 12, 2021 (HealthDay News) — In a report published online March 4 in the Journal of the American College of Radiology<\/em>, guidelines are provided for the management of unilateral axillary lymphadenopathy (UAL) identified on imaging tests in the context of COVID-19 vaccination.<\/p>\n Helen Anne D’Alessandro, M.D., from Massachusetts General Hospital in Boston, and colleagues present guidance for the management of UAL in individuals undergoing imaging tests for diverse medical reasons.<\/p>\n The authors note that providers and radiologists should be aware that UAL may be identified on diverse imaging examinations in patients recently vaccinated for COVID-19. On all intake forms, vaccination information should be documented (date, vaccination site, type of vaccine); this information should be accessible for radiologists at the time of exam interpretation. Ipsilateral UAL after recent (within the last six weeks) COVID-19 vaccination is a benign imaging finding in most clinical settings, and clinical follow-up is recommended rather than additional imaging or biopsy. A coordinated management plan is recommended in settings with a heightened pretest probability of malignancy, including additional imaging, short-interval follow-up, and biopsy; providers should be aware of a patient’s vaccination history and risk for metastatic lymphadenopathy. To avoid delays to vaccination and recommended imaging for optimal health care, clear guidelines should be communicated to patients and providers.<\/p>\n “Advanced planning can support our patients to feel confident and safe to receive their vaccinations as well as undergo recommended imaging in their usual care,” a coauthor said in a statement.<\/p>\n Several authors disclosed financial ties to the pharmaceutical, medical device, and medical technology industries.<\/p>\n